" class="no-js "lang="en-US"> Murat Tunaboylu - Medtech Alert
Monday, August 18, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Murat Tunaboylu

Murat Tunaboylu

About Murat Tunaboylu

Co-founded biotech companies Antiverse and Svarlight.
Previously, developed cell imaging software, built lab robots for cancer research, and automated Thermo Fisher Scientific’s gene synthesis laboratory.
 In finance, designed and improved high-frequency trading systems.

Related Story

Industry News

 Antiverse Collaborates with a Top 20 Pharma Company to Identify Antibody Drug Candidates Using AI Augmented Drug Discovery Platform | Pharmtech Focus

Antiverse Collaborates with a Top 20 Pharma Company to Identify Antibody Drug Candidates Using AI Augmented Drug Discovery Platform

January 31 2022

Antiverse, a biotechnology company developing a computational antibody drug discovery platform, today announced a partnership […]